Abbott Laboratories Stock Forecast, Price & News

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABT shares have increased by 40.9% and is now trading at $110.04.
View which stocks have been most impacted by COVID-19.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Abbott Laboratories stock.
View analyst ratings for Abbott Laboratories or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Abbott Laboratories.

Abbott Laboratories will be holding an earnings conference call on Wednesday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Wednesday, October, 21st. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.08. The healthcare product maker had revenue of $8.85 billion for the quarter, compared to analysts' expectations of $8.53 billion. Abbott Laboratories had a return on equity of 18.19% and a net margin of 10.50%. The company's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.84 earnings per share.
View Abbott Laboratories' earnings history.

Abbott Laboratories declared a quarterly dividend on Friday, December 11th. Stockholders of record on Friday, January 15th will be given a dividend of $0.45 per share on Tuesday, February 16th. This represents a $1.80 annualized dividend and a dividend yield of 1.64%. The ex-dividend date of this dividend is Thursday, January 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.36.
View Abbott Laboratories' dividend history.

Abbott Laboratories pays an annual dividend of $1.44 per share and currently has a dividend yield of 1.28%. Abbott Laboratories has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Abbott Laboratories is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 32.88% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.
View Abbott Laboratories' dividend history.

Abbott Laboratories issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, October, 21st. The company provided earnings per share (EPS) guidance of 3.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.32.

16 Wall Street analysts have issued 12 month price targets for Abbott Laboratories' shares. Their forecasts range from $94.00 to $130.00. On average, they anticipate Abbott Laboratories' stock price to reach $115.69 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price.
View analysts' price targets for Abbott Laboratories or view Wall Street analyst' top-rated stocks.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all of ABT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.10%), Gateway Investment Advisers LLC (0.04%), Huntington National Bank (0.03%), Park National Corp OH (0.03%), Tandem Investment Advisors Inc. (0.02%) and Atalanta Sosnoff Capital LLC (0.02%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Hexavest Inc., Gateway Investment Advisers LLC, State of Alaska Department of Revenue, Chesley Taft & Associates LLC, Park National Corp OH, Abner Herrman & Brock LLC, and IMS Capital Management. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories or view top insider-selling stocks.

ABT stock was purchased by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., IFM Investors Pty Ltd, Bath Savings Trust Co, Louisiana State Employees Retirement System, Cullinan Associates Inc., Trust Co. of Toledo NA OH, Vigilant Capital Management LLC, and Sowell Financial Services LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories or or view top insider-buying stocks.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $110.04.

Abbott Laboratories has a market capitalization of $195.03 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

The official website for Abbott Laboratories is www.abbott.com.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.